- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 7, 2024
Product Development
Clinical report: Calliditas data provide mixed support for anti-fibrotic cancer mechanism
Plus: J&J aiming to replace bladder cancer surgery with TAR-210, and updates from Merck, GlycoMimetics, EyePoint and more
BioCentury | Sep 15, 2022
Finance
Sept. 14 Quick Takes: Apollomics going public via SPAC deal
Plus RayzeBio raises $160M in series D for radiopharmaceuticals, and updates from Point, Larimar, Worg and more
BioCentury | Aug 8, 2022
Deals
Pfizer promises expanded global reach for sickle cell drug in $5.4B GBT takeout
Pharma gains rights to Oxbryta along with a sickle cell pipeline that could deliver $3B in peak sales
BioCentury | Nov 7, 2020
Finance
Apollomics anchors investor base in Asia with $124M raise as it readies for its next phase of growth
Ping An Capital leads series C round for cross-border cancer in-licensing play
BioCentury | Jan 7, 2020
Company News
Jan. 6 Company Quick Takes: China approvals for AZ, Sanofi and Gene+; plus Apollomics-GlycoMimetics, Pfizer-Merck KGaA and more
BioCentury | Sep 12, 2019
Distillery Therapeutics
Preventing metastasis in TNBC with liposome-delivered TRAIL
BioCentury | Jun 29, 2019
Finance
All eyes on new modality launches, cancer and rare disease data in 3Q19
Investors to watch new modality launches and cancer and rare disease data in a light 3Q19
BioCentury | Jul 6, 2018
Emerging Company Profile
Tethering bleeding risk
Tetherex’s antithrombotic therapy could reduce or eliminate risks of bleeding
Items per page:
1 - 10 of 71